Panel A shows a Western blot analysis with three rows of bands representing the expression of p53, p21, and Actin proteins in control and patient samples treated with actinomycin D for 0, 2, 4, 6, and 8 hours. The bands are labeled with molecular weights (50 kDa, 25 kDa, and 40 kDa). Panel B is a scatter plot showing the quantification of p53 slash Actin expression over time (0h, 2h, 4h, 6h, 8h) for control (CTL) and patient (P) samples, with significant differences indicated by double asterisks. Panel C is a scatter plot showing the quantification of p21 normalized to Actin expression over time (0h, 2h, 4h, 6h, 8h) for control (CTL) and patient (P) samples, with significant differences indicated by single asterisks and double asterisks. Panel D consists of four bar graphs showing the fold change in expression of p53, p21, PCNA, and BAX transcripts in control and patient samples, with significant differences indicated by single asterisks and double asterisks.
WDR75 variants are associated with increased p21 expression. (A–D) Expression of p53 and p21 protein from LCLs from controls and the patient untreated or treated with 5 nM Act D for 2, 4, 6, and 8 h (A). Representative image of n = 3 independent experiments (A). Quantification and statistical assessment for all experiments performed in A for p53 (B) and p21 (C) expression. Data were analyzed using the Mann–Whitney U test. *P < 0.05; **P < 0.001. Quantitative PCR analysis of p53, p21, PCNA, and BAX transcripts from LCLs from controls and the patient (D). n = 3 and for p21 n = 4 independent experiments ± SD. Data were analyzed using the Mann–Whitney test. *P < 0.05; **P < 0.001. Act D, actinomycin D. Source data are available for this figure: SourceData F3.